CONGRESS | #EHA2026 | POSTER Naveen Pemmaraju presents long-term results concerning thromboembolic and progression events in patients who enrolled in the phase II REVIVE trial (n = 70) and transitioned to the phase III open-label THRIVE trial (n = 46), evaluating rusfertide in phlebotomy-dependent patients with #PolycythemiaVera. - After >4 years of follow-up, 10% of patients had a thromboembolic event, all of whom had high-risk PV and other risk factors upon study entry. - ~70% of patients with prior thromboembolic events remained event-free while on the study. - The incidence of thromboembolic events was 3/100 PY. - Two of 70 patients had a post-PV progression event. These long-term data provide additional information on the occurrence of thromboembolic and progression events following rusfertide exposure. Longer-term follow-up will continue in the phase III setting. Follow our live feed for more updates: loom.ly/N2uNnTk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MPN #MPNsm #MedicalCongress @doctorpemm @MDAndersonNews